載入...
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countr...
Na minha lista:
| 發表在: | Clin Kidney J |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295603/ https://ncbi.nlm.nih.gov/pubmed/30581563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy089 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|